Summary

Peripheral Artery Disease Market Summary

The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. The intersecting forces of rising disease burden, continuous technological advancement, and demographic aging drive the peripheral artery disease (PAD) industry.

This alignment of unmet clinical needs with evolving therapeutic capabilities accelerates demand across care settings. The growing prevalence of diabetes and tobacco use remains a foundational force driving the market. Both risk factors contribute directly to the progression of atherosclerosis, the core pathological mechanism behind PAD. With diabetes rates climbing globally-particularly in aging, urban populations-and smoking still widespread in lower-income countries, the incidence of PAD continues to rise.

In March 2025, an Intermountain Health study presented at the ACC conference revealed that only 29.6% of women and 33.5% of men with symptomatic peripheral artery disease received full guideline-directed therapy. Among 7,522 patients tracked, the mortality rate exceeded 50%, underscoring severe gaps in diagnosis and treatment. Despite similar referral rates, women were less likely to receive optimal care. The study emphasized the need for improved screening protocols and focused PAD management.

Rapid innovation in endovascular technologies is reshaping treatment strategies and reinforcing market momentum. Next-generation tools such as drug-coated balloons, atherectomy systems, and bioresorbable stents offer improved efficacy, fewer complications, and shorter recovery times. These solutions are increasingly favored for treating complex lesions precisely while reducing restenosis and the need for repeat interventions. In March 2025, a study in Scientific Reports introduced DBMedDet, a deep-learning model that improved stent placement accuracy during endovascular procedures. With high precision (mAP 0.841) and real-time detection (127 FPS), it outperformed YOLO models in identifying stent boundaries across coronary, peripheral, and cerebrovascular cases.

Population aging further amplifies the market potential for PAD interventions, with individuals over 65 facing significantly elevated risk. Age-related arterial stiffening and the accumulation of comorbidities make this demographic especially vulnerable. In March 2025, the Aging Journal published findings from the Long Life Family Study showing individuals from long-lived families have a significantly lower risk of PAD. PAD prevalence among offspring of these families was only 1%, versus an expected 12%. Researchers linked this to protective genetic traits and healthier vascular profiles, identifying four genomic regions potentially tied to PAD resistance.

Global Peripheral Artery Disease Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peripheral artery disease market report based on device type, anatomical site, end use, and region:

• Device Type Outlook (Revenue, USD Million, 2021 - 2033)
• Endovascular Devices
• Surgical Devices
• Anatomical Site Outlook (Revenue, USD Million, 2021 - 2033)
• Aortoiliac
• Femoropopliteal
• Tibial
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Device Type
1.2.2. Anatomical Site
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecast timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity price analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Device Type Segment
2.2.2. Anatomical Site Segment
2.2.3. End Use Segment
2.2.4. Regional Outlook
2.3. Competitive Insights
Chapter 3. Global Peripheral Artery Disease Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of diabetes and smoking
3.2.1.2. Advancements in endovascular technologies
3.2.1.3. Growing elderly population and PAD risk
3.2.2. Market restraint analysis
3.2.2.1. High cost of advanced revascularization procedures
3.2.2.2. Limited access to PAD treatment in low-income regions
3.3. Peripheral Artery Disease Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Peripheral Artery Disease Market: Device Type Estimates & Trend Analysis
4.1. Peripheral Artery Disease Market: Device Type Dashboard
4.2. Peripheral Artery Disease Market: Device Type Movement Analysis
4.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by Device Type, 2021 - 2033 (USD Million)
4.4. Endovascular Devices
4.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
4.5. Surgical Devices
4.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 5. Peripheral Artery Disease Market: Anatomical Site Estimates & Trend Analysis
5.1. Peripheral Artery Disease Market: Anatomical Site Dashboard
5.2. Peripheral Artery Disease Market: Anatomical Site Movement Analysis
5.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by Anatomical Site, 2021 - 2033 (USD Million)
5.4. Aortoiliac
5.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
5.5. Femoropopliteal
5.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
5.6. Tibial
5.6.1. Market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 6. Peripheral Artery Disease Market: End Use Estimates & Trend Analysis
6.1. Peripheral Artery Disease Market: End Use Dashboard
6.2. Peripheral Artery Disease Market: End Use Movement Analysis
6.3. Peripheral Artery Disease Market Size & Forecasts and Trend Analysis, by End Use, 2021 - 2033 (USD Million)
6.4. Hospitals
6.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
6.5. Outpatient Facilities
6.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 7. Peripheral Artery Disease Market: Regional Estimates & Trend Analysis by Country, Device Type, Anatomical Site & End Use
7.1. Global Peripheral Artery Disease Market: Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2021 - 2033
7.3. North America
7.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Regulatory framework/ reimbursement structure
7.3.4.3. Competitive scenario
7.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
7.4. Europe
7.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
7.4.8. Norway
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
7.4.9. Denmark
7.4.9.1. Key country dynamics
7.4.9.2. Regulatory framework/ reimbursement structure
7.4.9.3. Competitive scenario
7.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
7.5. Asia Pacific
7.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
7.5.3. Japan
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
7.5.7. South Korea
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework/ reimbursement structure
7.5.7.3. Competitive scenario
7.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
7.6. Latin America
7.6.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
7.7. MEA
7.7.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
7.7.3. South Africa
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Manufacturers
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. BD
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Bentley InnoMed
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Scitech Medical
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Abbott Laboratories
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Boston Scientific Corporation
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. W. L. Gore & Associates, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Medtronic
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Cook
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Terumo Corporation
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. iVascular
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Getinge AB
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. Biotronik SE & Co KG
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives